Spectral Medical Inc T.EDT

The difference exposure makes ?

[mercedesman]

May 31, 2023

Introduction

 

Cytokine adsorption using the CytoSorb® adsorber has been proposed in various clinical settings including sepsis, ARDS, hyperinflammatory syndromes, cardiac surgery or recovery after cardiac arrest. The aim of this analysis is to provide evidence for the efficacy of the CytoSorb® adsorber with regard to mortality in various settings.
 

Conclusion

In conclusion, there is no evidence of a reduction in mortality by treatment with CytoSorb® in any of the examined conditions. Therefore, we cannot recommend the use of CytoSorb® in intensive care patients unless clear evidence is generated. We need adequately designed RCTs in specific medical conditions targeting the right patients. Hence, ground work needs to be undertaken to identify patients likely to respond to the therapy, e.g. very high cytokine levels, and the optimal time point for therapy of the respective condition.

https://ccforum.biomedcentral.com/articles/10.1186/s13054-023-04492-9

Contrast the above with various RWE, including meta-analyses, and of late, Euphas 2 results, on PMX 

AND YET....

CTSO Market Cap  $152 M USD

EDT Market Cap $72 M CAD 


The biggest difference?

Besides the fact ....one is proven to work and is in a late stage 3b "confirmatory" RCT with results to date that are "exceeding expectations" and that are consistent with recently released Euphas 2 data showing a high mortality benefit....?

One trades on Nasdaq, the other on the lowest level of OTC pinks. 
 

And this is not an exposure issue? 

Efficient Market Hypothesis you say? 

Hmmmmmmm!?

MM